Literature DB >> 12202283

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.

Hsien-Yuan Lane1, Yue-Cune Chang, Chih-Chiang Chiu, Mao-Liang Chen, Min-Hua Hsieh, Wen-Ho Chang.   

Abstract

OBJECTIVE: This study investigated the effect of the 102-T/C polymorphism in the 5-HT(2A) receptor gene on risperidone efficacy.
METHOD: One hundred Han Chinese patients with acutely exacerbated schizophrenia were given risperidone for up to 42 days. The patients were genotyped for 5-HT(2A) polymorphisms. Psychopathology was measured biweekly with the Positive and Negative Syndrome Scale while the patients were taking risperidone. Generalized estimating equation methods were used to analyze the effects of treatment duration, T/C genotypes, and other prognostic factors on Positive and Negative Syndrome Scale performance.
RESULTS: Patients with the C/C genotype had lower total scores, negative subscale scores, and general psychopathology scores but not positive subscale scores on the Positive and Negative Syndrome Scale than patients with the 102-T/C genotype. Patients with the T/C and T/T genotypes had comparable total and subscale scores. The number of previous hospitalizations and the dose of risperidone also affected Positive and Negative Syndrome Scale total scores.
CONCLUSIONS: These results suggest that variations in the 5-HT(2A) receptor gene may influence individual responses to risperidone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202283     DOI: 10.1176/appi.ajp.159.9.1593

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  24 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

3.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

Review 4.  Central nervous system drug development: an integrative biomarker approach toward individualized medicine.

Authors:  B Gomez-Mancilla; E Marrer; J Kehren; A Kinnunen; G Imbert; R Hillebrand; M Bergström; M E Schmidt
Journal:  NeuroRx       Date:  2005-10

5.  Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults.

Authors:  Hsien-Yuan Lane; Yi-Ching Liu; Chieh-Liang Huang; Ching-Liang Hsieh; Yi-Lin Chang; Lauren Chang; Yue-Cune Chang; Wen-Ho Chang
Journal:  J Psychiatry Neurosci       Date:  2008-01       Impact factor: 6.186

Review 6.  The genetics of obsessive-compulsive disorder and Tourette's syndrome: what are the common factors?

Authors:  Marco A Grados
Journal:  Curr Psychiatry Rep       Date:  2009-04       Impact factor: 5.285

7.  Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

Authors:  Anna C Need; Richard S E Keefe; Dongliang Ge; Iris Grossman; Sam Dickson; Joseph P McEvoy; David B Goldstein
Journal:  Eur J Hum Genet       Date:  2009-01-21       Impact factor: 4.246

Review 8.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 9.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

10.  Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.

Authors:  Hsien-Yuan Lane; Yue-Cune Chang; Chih-Chiang Chiu; Sue-Hong Lee; Cher-Yeang Lin; Wen-Ho Chang
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.